X4 Pharma Reports Positive Outcome Of Type C Meeting With FDA Related To 4WARD Phase 3 Trial

X4 Pharmaceuticals announced a positive Type C meeting outcome with the FDA regarding its global 4WARD Phase 3 clinical trial. The meeting aligned the company and regulator on a revised trial sample size, associated statistical power, and safety-database size, reducing regulatory uncertainty around the study design and supporting the program's development path.